Search Result

Results for "

PARP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (228) Adenosine Receptor (1) Adrenergic Receptor (1) Akt (3) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (3) Antibiotic (2) Apoptosis (101) Arenavirus (2) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Aurora Kinase (1) Autophagy (17) Bacterial (3) Bcl-2 Family (13) c-Met/HGFR (1) c-Myc (1) Caspase (29) CDK (8) Ceramidase (1) CFTR (2) Checkpoint Kinase (Chk) (1) Deubiquitinase (1) Dipeptidyl Peptidase (1) DNA-PK (1) DNA/RNA Synthesis (5) Drug Metabolite (1) Dynamin (1) E3 Ligase Ligand-Linker Conjugates (4) EGFR (2) Endogenous Metabolite (12) Epigenetic Reader Domain (5) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FGFR (3) Fluorescent Dye (2) HDAC (8) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) HSP (1) IAP (1) IGF-1R (1) IKK (1) Influenza Virus (1) IRAK (1) Isotope-Labeled Compounds (2) JNK (2) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (3) Microtubule/Tubulin (8) Mitochondrial Metabolism (1) Mitophagy (5) Molecular Glues (2) Necroptosis (1) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (3) p38 MAPK (5) Parasite (6) PD-1/PD-L1 (2) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (3) Poly(ADP-ribose) Glycohydrolase (PARG) (3) PPAR (3) PROTAC Linkers (2) PROTACs (9) Proteasome (1) Raf (1) Ras (1) Reactive Oxygen Species (5) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) Sirtuin (6) Small Interfering RNA (siRNA) (25) STAT (2) Survivin (2) Target Protein Ligand-Linker Conjugates (1) Topoisomerase (3) VEGFR (3) Wnt (1)
By Research Areas:	Cancer (279) Cardiovascular Disease (8) Infection (8) Inflammation/Immunology (18) Metabolic Disease (8) Neurological Disease (26)
Click Chemistry:	PROTAC Synthesis (1) Azide (3) Alkynes (2)
Oligonucleotides:	Nucleosides and their Analogs (4) Nucleoside Phosphoramidites (2) Pre-designed siRNA Sets (25) siRNAs (25)

353

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization .

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active *PARP-1* inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting *PARP-1* in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting *PARP-1* activity in cancer .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-159612

PARP1-IN-28	PARP	Cancer
PARP1-IN-28 (compound 1) is a *PARP1* inhibitor. PARP1-IN-28 can be used in the study of cancer .

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-D1188

PARP7-probe-1	PARP	Cancer
PARP7-probe-1 is a chemiluminescent labeled *PARP7* probe. PARP7-probe-1 is a biotinylated probe binding to the PARP7 active site. PARP7-probe-1 can be used for the research of PARP7 function .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-164757

PARP-1-IN-32	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PARP-1-IN-32 (compound 15) is a poly (ADPribose) polymerase-1 (PARP-1) inhibitor. PARP-1-IN-32 can be used in cancer research .

HY-102035

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-132297

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-163658

PARP-1-IN-23	PARP	Cancer
PARP-1-IN-23 (Compound I16 ) is an orally active and selective *PARP-1* inhibitor with the IC₅₀ of 12.38 nM. PARP-1-IN-23 inhibits tumor growth in vivo .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-168094

PARP1-IN-30	PARP	Cancer
PARP1-IN-30 (Compound 3) is a specific and potent *PARP1* inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of *PARP1* in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-155122

PARP-1-IN-13	PARP	Cancer
PARP-1-IN-13 (Compound 19c) is a *PARP-1* inhibitor (IC₅₀: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway .

HY-151609

PARP7-IN-12	PARP	Cancer
PARP7-IN-12 is a potent *PARP7* Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

HY-163492

PARP7-IN-19	PARP	Cancer
PARP7-IN-19 (compound 5a) is an inhibitor of *PARP7* ( IC₅₀ ≤10nM). PARP7-IN-19 can be used in the research area of tumors .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of *PARP7* with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-162114

PARP1-IN-18	PARP	Cancer
PARP1-IN-18 (compound 25) is a potent *PARP1* inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

HY-149001

PARP1-IN-9	PARP	Cancer
PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC₅₀ of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .

HY-162172

PARP7-IN-18	PARP	Cancer
Parp7-in-18 (Compund 8) is a selective *PARP7* inhibitor with an IC₅₀ of 0.11 nM. PARP7-IN-18 exhibits good anticancer activity and pharmacokinetic properties .

HY-144642

PARP-1-IN-1	PARP	Cancer
PARP-1-IN-1 is a high selective and orally active *PARP-1* inhibitor (IC₅₀=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Cancer
PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated *PARP1* inhibitor, with an IC₅₀ of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-156419

PARP7-IN-16	PARP	Cancer
PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of *PARP-1/2/7, with IC₅₀s of 0.94, 0.87 and 0.21 nM, respectively. PARP*7-IN-16 can be used for the research of breast cancer and prostate cancer .

HY-146502

PARP10/15-IN-3	PARP Apoptosis	Cancer
PARP10/15-IN-3 (Compound 8a) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis .

HY-150765

PARP1-IN-12	PARP Apoptosis	Cancer
PARP1-IN-12 is a potent *PARP1* inhibitor with an IC₅₀ of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in BRCA-deficient cells .

HY-156298

PARP1-IN-16	PARP Apoptosis	Cancer
PARP1-IN-16 (compound 12a) is a potent *PARP1* inhibitor, with an IC₅₀ of 1.89 nM. PARP1-IN-16 can arrest the cell cycle in S phase and induce apoptosis in HCT-116 cells .

HY-158680

PARP1-IN-21	PARP	Cancer
PARP1-IN-21 (example 16) is a potent inhibitor of *PARP1, with the IC₅₀* of ＜ 10 nM .

HY-158681

PARP1-IN-22	PARP	Cancer
PARP1-IN-22 (compound 15) is a potent inhibitor of *PARP1, with the IC₅₀* of ＜ 10 nM .

HY-161607

PARP7-IN-21	PARP	Cancer
PARP7-IN-21 (compound 128) is a potent inhibitor of *PARP7, with the IC₅₀* of ＜ 10 nM .

HY-146501

PARP10/15-IN-2	PARP Apoptosis	Cancer
PARP10/15-IN-2 (Compound 8h) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.15 µM and 0.37 µM against PARP10 and PARP15, respectively. PARP10/15-IN-2 is able to enter cells and rescue cells from apoptosis .

HY-160417

PARP1-IN-19	PARP	Cancer
PARP1-IN-19 is a *PARP1* inhibitor with antitumor effects (CN107955001A; Embodiment 3) .

HY-143398

PARP10/15-IN-1	PARP	Cancer
PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of *PARP10* and *PARP15, with IC₅₀s of 160 nM and 370 nM, respectively. PARP*10/15-IN-1 can be used for cancer .

HY-142657

PARP1-IN-7	PARP	Cancer
PARP1-IN-7 is an inhibitor of poly(ADP-ribose) polymerase-1 (PARP1) as an anticancer agent.

HY-163719

PARP7-IN-22	PARP	Cancer
PARP7-IN-22 (XLY-1) is a *PARP7* inhibitor with an IC₅₀ of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .

HY-145328

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated *PARP1* inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .

HY-155351

PARP7-IN-15	PARP	Cancer
PARP7-IN-15 (Compound 18) is a PARP7 inhibitor with IC₅₀ of 0.56 nM, that has antitumor activity .

HY-162349

PARP7/HDACs-IN-1	HDAC PARP	Cancer
PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting *PARP7/HDAC* with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC₅₀s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a *PARP1/2/CDK12* inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-163817

PARP1/2-IN-3	PARP	Cancer
PARP1/2-IN-3 (Compound 29) is an orally active inhibitor for PARP 1 and PARP 2 with IC₅₀ of 0.2235 nM and <0.001 nM. PARP1/2-IN-3 inhibits the proliferation of Capan-1 wildtype, AZD2281 or BMN673 resistant cells with IC₅₀ of 1.82-9.98 nM. PARP1/2-IN-3 exhibits antitumor efficacy in mice .

HY-149003

PARP1-IN-10	PARP Apoptosis	Cancer
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent *PARP1* inhibitor with an IC₅₀ value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .

HY-139879

PARP1-IN-6	PARP	Cancer
PARP1-IN-6 is a dual *tubulin/PARP-1* inhibitor with IC₅₀ values of 0.94 and 0.48 μM, respectively.

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

2,030 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,030 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L188

Anti-Brain Cancer Compound Library

1,546 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,546 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

Cat. No.	Product Name	Target	Research Area

HY-P3993A

(Gly14)-Humanin (human) (acetate) 14-Glycine-Humanin (human) (acetate)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) acetate is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) acetate has anti-apoptotic and neuroprotective functions .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-P3993

(Gly14)-Humanin (human) 14-Glycine-Humanin (human)	Apoptosis	Neurological Disease
(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) has anti-apoptotic and neuroprotective functions .

HY-P10285

d-KLA Peptide D-(KLAKLAK)2	Mitochondrial Metabolism PARP Caspase	Cancer
d-KLA Peptide is a synthetic pro-apoptotic peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide activates biochemical pathways associated with apoptosis, including the activation of caspase family proteins and *PARP* (poly ADP ribose polymerase). d-KLA Peptide can be used to carry and deliver genes or small molecules to enhance anti-tumor effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6818

5,7,4'-Trimethoxyflavone	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Disease Research Fields Zingiberaceae Cancer	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase *(PARP)* protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Other disease Classification of Application Fields Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N1988

Cucurbitacin IIa Hemslecin A	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Cancer	Survivin Apoptosis
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-N7569

Demethoxyfumitremorgin C	Structural Classification Alkaloids Microorganisms Source classification Marine natural products Other marine organisms Indole Alkaloids	Apoptosis Caspase PPAR
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-P2569

Malformin A1	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-N10481

Aviculin	Classification of Application Fields Polygonum aviculare L. Polygonaceae Source classification Lignans Phenylpropanoids Plants Disease Research Fields Cancer	Apoptosis Caspase PARP Bcl-2 Family
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC₅₀ of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio .

HY-N6818R

5,7,4'-Trimethoxyflavone (Standard)	Structural Classification Flavonoids Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Zingiberaceae	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,?7,?4'-Trimethoxyflavone (Standard) is the analytical standard of 5,?7,?4'-Trimethoxyflavone. This product is intended for research and analytical applications. 5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-130476

Satratoxin G	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Caspase Apoptosis
Satratoxin G is a large cyclic mucor toxin. Satratoxin G induces apoptosis by activation of caspase .

HY-N6861

Lucidenic acid B	Triterpenes Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Polyporaceae Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Lucidenic acid B is a natural compound isolated from Ganoderma lucidum, induces apoptosis of cancer cells, and causes the activation of caspase-9 and caspase-3, and cleavage of PARP. Lucidenic acid B does not affect the cell cycle profile, or the number of necrotic cells .

HY-N3584

Paris saponin VII 2 Publications Verification Chonglou Saponin VII	Structural Classification Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of *Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-N1988R

Cucurbitacin IIa (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl.	Survivin Apoptosis
Cucurbitacin IIa (Standard) is the analytical standard of Cucurbitacin IIa. This product is intended for research and analytical applications. Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-N3825

ent-Kaurane-3α,16β,17-triol	Structural Classification Terpenoids Source classification Euphorbia stracheyi Boiss. Diterpenoids Euphorbiaceae Plants	Apoptosis
ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674A

Dehydrocorydaline chloride Maximum Cited Publications 27 Publications Verification 13-Methylpalmatine chloride	Infection Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline chloride shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N1970

5,7-Dihydroxychromone 1 Publications Verification	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved *PARP* in 6-OHDA-induced SH-SY5Y cells .

HY-Z0283R

Benzamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674

Dehydrocorydaline Maximum Cited Publications 27 Publications Verification 13-Methylpalmatine	Infection Alkaloids Structural Classification Corydalis yanhusuo W. T. Wang Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline shows strong anti-malarial effects (IC₅₀=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674B

Dehydrocorydaline (hydroxyl) Maximum Cited Publications 27 Publications Verification 13-Methylpalmatine (hydroxyl)	Structural Classification Alkaloids Corydalis yanhusuo W. T. Wang Source classification Plants Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

HY-N4238

Dehydrocorydaline nitrate Maximum Cited Publications 27 Publications Verification 13-Methylpalmatine nitrate	Infection Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. . Dehydrocorydaline nitrate shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N6969A

Dicentrine hydrochloride	Structural Classification Alkaloids Other Alkaloids Source classification Stephania epigaea Lo Plants Menispermaceae	Adrenergic Receptor
Dicentrine hydrochloride is a drug with anti-inflammatory and anti-cancer activity. Dicentrine hydrochloride exerts its effects by enhancing TNF-α-induced apoptosis in A549 lung adenocarcinoma cells. Dicentrine hydrochloride increases caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) activities. Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells. Dicentrine hydrochloride significantly inhibited the TNF-α-activated TAK1, p38, JNK and Akt signaling pathways, and reduced the transcriptional activities of NF-κB and AP-1 .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone. This product is intended for research and analytical applications. 5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved PARP in 6-OHDA-induced SH-SY5Y cells .

HY-127057

Lambertianic acid	Pinus lambertiana Douglas Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Plants	Androgen Receptor CDK MDM-2/p53 Apoptosis Caspase PARP Bcl-2 Family
Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer .

HY-123033A

Nicotinamide riboside chloride 10+ Cited Publications	Alkaloids Structural Classification Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Pyridine Alkaloids Metabolic Disease Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033

Nicotinamide riboside	Natural Products Human Gut Microbiota Metabolites Microorganisms Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Sirtuin Endogenous Metabolite
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-N8572

3',4'-Dimethoxyflavone	Structural Classification Flavonoids other families Flavones Coniogramme japonica (Thunb.) Diels Plants	PARP Reactive Oxygen Species Aryl Hydrocarbon Receptor
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of *PARP* and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .

Species:	Human (9) Mouse (1)
Tag:	His (7) Strep (2) Tag Free (1) Avi (1) GST (2) Flag (1)
Source:	Sf9 insect cells (1) Sf9 insect cells (4) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P74652

	PARP1 Protein, Human (sf9, His) ADPRT 1; ADPRT; PARP apoptosis; PARP; PPOL	Human	Sf9 insect cells
	The PARP1 protein is a polyADP-ribosyltransferase that crucially mediates polyADP-ribosylation (PARsylation) in DNA repair, including base excision and double-strand breaks. By interacting with factors such as HPF1 and NMNAT1, the specificity of PARP1 extends to various amino acids. PARP1 Protein, Human (sf9, His) is the recombinant human-derived PARP1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of PARP1 Protein, Human (sf9, His) is 1014 a.a., with molecular weight of 100-110 kDa.

HY-P73337

	PARP Protein, Mouse (sf9, His) ADPRT 1; ADPRT; PARP apoptosis; PARP; PPOL	Mouse	Sf9 insect cells
	PARP, a poly-ADP-ribosyltransferase, catalyzes poly-ADP-ribosylation, crucial for DNA repair. This protein irreversibly binds to DNA breaks, disrupting repair processes and triggering DNA damage-induced apoptosis. PARP Protein, Mouse (sf9, His) is the recombinant mouse-derived PARP protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P702585

	PARP2 Protein, Human (sf9, His) Poly [ADP-ribose] polymerase 2; ADP-ribosyltransferase diphtheria toxin-like 2; DNA ADP-ribosyltransferase PARP2; NAD(+) ADP-ribosyltransferase 2; ADPRT-2; pADPRT-2; EC:2.4.2.30; ADPRT2; ADPRTL2	Human	Sf9 insect cells

HY-P703622

	PARP7 Protein, Human (His) PARP7	Human	E. coli
	PARP7 Protein, Human (His) is the recombinant human-derived PARP7, expressed by E. coli , with His labeled tag. ,

HY-P702866

	PARP3 Protein, Human (His, Strep) Protein mono-ADP-ribosyltransferase PARP3; ARTD3; IRT1; ADPRT-3; PARP-3	Human	E. coli
	The PARP3 protein is a mono-ADP ribosyltransferase that responds to DNA damage, focusing on mono-ADP ribosylation of proteins such as histone H2B, XRCC5, and XRCC6. PARP3 plays a key role in the DNA repair process, participating in precise nonhomologous end joining and inhibiting G-quadruplex structure. PARP3 Protein, Human (His, Strep) is the recombinant human-derived PARP3 protein, expressed by E. coli , with N-His, N-Strep II labeled tag.

HY-P702868

	PARP6 Protein, Human (sf9, GST) PARP6; Protein mono-ADP-ribosyltransferase PARP6; ADP-ribosyltransferase diphtheria toxin-like 17; ARTD17; Poly [ADP-ribose] polymerase 6; PARP-6	Human	Sf9 insect cells
	PARP6 protein, a mono-ADP-ribosyltransferase, specializes in mediating the mono-ADP-ribosylation of target proteins. PARP6 Protein, Human (sf9, GST) is the recombinant human-derived PARP6 protein, expressed by Sf9 insect cells , with GST labeled tag.

HY-P701955

	PARP6 Protein, Human (sf9, FLAG, GST, Avi) PARP6; Protein mono-ADP-ribosyltransferase PARP6; ADP-ribosyltransferase diphtheria toxin-like 17; ARTD17; Poly [ADP-ribose] polymerase 6; PARP-6	Human	Sf9 insect cells
	PARP6 protein, a mono-ADP-ribosyltransferase, specializes in mediating the mono-ADP-ribosylation of target proteins. PARP6 Protein, Human (sf9, FLAG, GST, Avi) is the recombinant human-derived PARP6 protein, expressed by Sf9 insect cells , with C-Avi, N-Flag, N-GST labeled tag.

HY-P701951

	PARP14 Protein, Human PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human is the recombinant human-derived PARP14 protein, expressed by E. coli , with tag free. The total length of PARP14 Protein, Human is 180 a.a., .

HY-P701952

	PARP14 Protein, Human (His, Strep) PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human (His, Strep) is the recombinant human-derived PARP14 protein, expressed by E. coli , with N-Strep, N-8*His labeled tag. The total length of PARP14 Protein, Human (His, Strep) is 180 a.a., .

HY-P701953

	PARP15 Protein, Human (His) PARP15; Protein mono-ADP-ribosyltransferase PARP15; ADP-ribosyltransferase diphtheria toxin-like 7; ARTD7; B-aggressive lymphoma protein 3; Poly [ADP-ribose] polymerase 15; PARP-15	Human	E. coli
	PARP15 protein, acting as a mono-ADP-ribosyltransferase, facilitates the mono-ADP-ribosylation of target proteins. It also functions as a transcriptional negative regulator, impacting cellular processes and gene expression. PARP15 Protein, Human (His) is the recombinant human-derived PARP15 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PARP15 Protein, Human (His) is 176 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5
Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

HY-Z0283S

Benzamide-15N
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-10162S1

Olaparib-d8
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80263

	PARP1 Antibody PARP-1; ARTD1; ADPRT 1; PARP1	WB, ICC/IF, IHC-P, FC	Human, Mouse
	PARP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to PARP. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P80265

	PARP2 Antibody	WB, FC	Human
	PARP2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 66 kDa, targeting to PARP2. It can be used for WB,FC assays with tag free, in the background of Human.

HY-P80780

	PARP1 Antibody (YA245) PARP1; ADPRT; PPOL; Poly [ADP-ribose] polymerase 1; PARP-1; ADP-ribosyltransferase diphtheria toxin-like 1; ARTD1; NAD(+) ADP-ribosyltransferase 1; ADPRT 1; Poly[ADP-ribose] synthase 1	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	PARP1 Antibody (YA245) is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to PARP1. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80448

	*Cleaved PARP* Antibody** 1 Publications Verification	WB, ICC/IF, IP, FC	Human
	Cleaved PARP Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 89 kDa, targeting to Cleaved PARP. It can be used for WB,ICC,IP,FC assays with tag free, in the background of Human.

HY-P80625

	*Cleaved-PARP1 Antibody* PARP1; ADPRT; PPOL; Poly [ADP-ribose] polymerase 1; PARP-1; ADP-ribosyltransferase diphtheria toxin-like 1; ARTD1; NAD(+) ADP-ribosyltransferase 1; ADPRT 1; Poly[ADP-ribose] synthase 1	WB	Human
	Cleaved-PARP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to Cleaved-PARP1. It can be used for WB assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150221

DB008		Alkynes
DB008 is potent and selective *PARP16* inhibitor with an IC₅₀ value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130652

Pomalidomide 4'-PEG3-azide		Azide
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient *PARP1*?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W021401

Amino-PEG3-C2-Azido		PROTAC Synthesis Azide
Amino-PEG3-C2-Azido is a PEG-based PROTAC linker can be used in the synthesis of the PARP1 degrader iRucaparib-TP3 (HY-130645) . Amino-PEG3-C2-Azido is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3		Azide
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM . (S,R,S)-AHPC-C2-PEG4-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-RS10047

PARP1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP1 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10048

Parp1 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10049

Parp1 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10050

PARP10 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP10 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10051

Parp10 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10052

Parp10 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10053

PARP11 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP11 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10054

PARP12 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP12 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10055

PARP14 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP14 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10056

Parp14 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10057

Parp14 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp14 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp14 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10058

PARP15 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP15 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10059

PARP16 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP16 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10060

PARP2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP2 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10061

Parp2 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10062

Parp2 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10063

PARP3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP3 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10064

Parp3 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10065

Parp3 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10066

PARP4 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP4 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10067

Parp4 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10068

Parp4 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Parp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10069

PARP6 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP6 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10070

PARP8 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP8 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10071

PARP9 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PARP9 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-152696

6-O-Methylinosine		Nucleosides and their Analogs
6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154017

2′-C-Methyl-6-O-methylinosine		Nucleosides and their Analogs
2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154393

2-Chloro-2'-deoxy-6-O-methylinosine		Nucleosides and their Analogs
2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152678

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside		Nucleosides and their Analogs
6-Methoxypurine-9-β-D-5’(R)-C-methylriboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W141392

2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W392836

2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites
2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks